MMRV Vaccination Does Not Increase Febrile Seizure Risk MMRV Vaccination Does Not Increase Febrile Seizure Risk

Giving the combination measles-mumps-rubella-varicella (MMRV) vaccine as the second dose of measles-containing vaccine does not appear to increase the risk of febrile seizures, researchers from Australia report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news

Related Links:

CONCLUSION: The demonstration of batch consistency and non-inferiority of the Bio-MMR vaccine completed the technology transfer. This is a significant technological achievement with implications for immunisation programs. PMID: 30843921 [PubMed - in process]
Source: Memorias do Instituto Oswaldo Cruz - Category: Infectious Diseases Authors: Tags: Mem Inst Oswaldo Cruz Source Type: research
CONCLUSION: Demonstration of early disappearance of maternal antibodies against MMRV viruses leading to the risk of these infections at an early age emphasize need for early immunization of Indian children. Suboptimal response to measles vaccine needs to be seriously addressed especially in view of the WHO's initiative for measles eradication. PMID: 30765170 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
ConclusionsConsiderable vaccination delay should be addressed within the vaccine hesitancy spectrum. Delays may induce susceptibility to vaccine-preventable disease outbreaks; tailored programmes to improve timeliness are required. PMID: 30755293 [PubMed - in process]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research
CONCLUSION: This investigation suggested that most large local reactions were causally associated with the Infanrix-hexa® vaccine and that the risk was not greater when ProQuad® and Infanrix-hexa® were administered in the same limb. Given the improved vaccine coverage for hepatitis B, benefit-risk analysis likely still favours ongoing use of Infanrix-hexa® with informed parental consent. PMID: 30269915 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Authors: Devecioğlu E, Gökçay G, Boran P, Eren T, Yılmaz G, Badur S Abstract The protection of infants against infections during the first few months of life is provided mainly by maternal antibodies. The presence of maternal antibodies can decrease vaccine efficacy. The waning time of maternal antibodies shows variations therefore seroepidemiological studies are important for the development of vaccination schedules. Some recent studies showed that the maternal measles antibodies may disappear around 3 months of age especially in infants born from mothers who were vaccinated. There are few cross-sect...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
Abstract This post-hoc analysis of data from a matched cohort study investigated the risk of febrile convulsions (FC) 5-12 days post-first dose of measles-mumps-rubella-varicella vaccine (MMRV) in a low-risk population, compared to measles-mumps-rubella (MMR) and varicella (V) vaccines administered separately. The low-risk population excluded children with personal history of FC (Scenario 1) and children with personal or/and family history (≥1 parent/sibling) of FC (Scenario 2). Incidence of FC post-MMRV in Scenario 2 (excluding at risk children) (36.3-49.5/100,000) and post-MMR+V in the whole cohort includin...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
The objective of this analysis was to evaluate the health and economic implications of scheduling options for a transition to two dose UVV, considering both monovalent varicella vaccines (V) and quadrivalent measles-mumps-rubella-varicella vaccines (MMRV) in Argentina.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Type: Electronic/Moderated Poster Presentation Source Type: research
CONCLUSION: Non-inferiority of dTap-IPVB to dTap-IPVR was demonstrated. Both vaccines had a clinically acceptable safety and reactogenicity profile when co-administered with MMRV to children 3-4 years old. TRIAL REGISTRATION: NCT01245049 (ClinicalTrials.gov). PMID: 29576304 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Macartney et al report in this issue ofJAMA Pediatrics on the safety of using combination measles-mumps-rubella-varicella (MMRV) vaccine as the second dose of measles-mumps-rubella (MMR) vaccine and sole dose of varicella vaccine in Australia, and the effect of this policy on national vaccine coverage. They found that there was no increase in febrile seizures when MMRV is administered in the second year of life approximately 6 months after a first dose of MMR and that on-time vaccination increased with use of MMRV. Are these findings an indication that the timing and use of combination MMRV vaccine should be reconsidered f...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
Macartney et al report in this issue ofJAMA Pediatrics on the safety of using combination measles-mumps-rubella-varicella (MMRV) vaccine as the second dose of measles-mumps-rubella (MMR) vaccine and sole dose of varicella vaccine in Australia, and the effect of this policy on national vaccine coverage. They found that there was no increase in febrile seizures when MMRV is administered in the second year of life approximately 6 months after a first dose of MMR and that on-time vaccination increased with use of MMRV. Are these findings an indication that the timing and use of combination MMRV vaccine should be reconsidered f...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
More News: Australia Health | Health | Measles | Measles Vaccine | MMR (Measles,Mumps,Rubella) Vaccine | Mumps | Mumps Vaccine | Rubella | Rubella Vaccine | Vaccines